Full-Time

Head of Market Access

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$284k - $355kAnnually

Expert

San Carlos, CA, USA

In-office at least 3 days per week.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary

You match the following Revolution Medicines's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Minimum of fifteen (15) years of biopharmaceutical market access experience, including payer, reimbursement, pricing & contracting, field team leadership, and established relationships with several key national and regional payers.
  • Strong understanding of healthcare policy, payer dynamics, healthcare system, and regulatory landscape.
  • Deep understanding of and compliance with the OIG and FDA regulations.
Responsibilities
  • Develop RevMed’s market access strategy and tactics to ensure successful initial product launches and maximization of lifecycle value.
  • Design and lead execution of access, reimbursement & pricing plans.
  • Provide strategic leadership and direction for payer access, coverage, reimbursement, patient support services, pricing and distribution, list and net pricing, and contracting across all payer types.
  • Design and drive the strategic plan for market access capabilities within the US (and globally as needed) including strategic account management, patient access programs, trade and distribution, contracting, and health economics and pricing.
  • Develop US pricing recommendations to ensure alignment as it relates to contracting, rebating, price adjustments, best price, and other related elements.
  • Work collaboratively to recommend and execute a US managed care strategy for payer and key channels, including commercial insurers, Pharmacy Benefit Managers (PBMs), Integrated Health Networks (IHN), State Medicaid, Medicare, and Federal VA/DoD channels.
  • Proactively meet with senior leadership at key U.S. payers to identify opportunities for broader collaboration and partnership, including both regional and national health plans.
  • Collaborate with Marketing in the development of the product value proposition and other resources for payer account managers, and pull-through communications and resources for the US field team(s).
  • Oversee the design and execution of the patient support services hub.
  • Build and lead a high-functioning Market Access team and infrastructure to ensure optimal access solutions for patients and providers, including the appropriate field-based customer team to ensure optimal access.
  • In partnership with Medical Affairs and Clinical Development, ensure clinical research incorporates HEOR needs, and be responsible for the health economic and broader value assessment. Oversee the development of budget impact and cost-effectiveness models.
Desired Qualifications
  • BS/BA degree; master’s degree or higher preferred.
  • Broad commercial experience including oncology product launches.
  • Proven leadership experience building from the ground up and leading high-performing teams.
  • Excellent communication and negotiation skills.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in net cash for R&D.
  • FDA fast-tracking RAS-targeted therapies supports their pipeline development.
  • Increased interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

7%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.